Live Analyst Rating Changes 30667 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matthew Weston
UBS

Matthew Weston

UBS
Wall Street Analyst
★★★★☆
#621
on 13Foresight · ranked by our own returns
53%
Success Rate
+2.2%
Average Return
23 of 43 calls profitable · -97.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 53% of Matthew Weston's ratings turned a profit when each position was held for 1 year — averaging +2.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

61 Buy 81 Hold 0 Sell
Matthew's Stock Coverage 16 ratings · 2026-09-08
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
DE:BAYN
Bayer
 Sep 01, 2026 BUY Strong Buy
+9.0% avg upside
31 analysts
$62.00
25.39% Upside
 -0.7% ·
CH:NOVN
Novartis AG
 Sep 01, 2026 HOLD Buy
-6.0% avg upside
32 analysts
$116.00
3.74% Upside
 -1.3% ·
FR:DIM
Sartorius Stedim Biotech
 Aug 20, 2026 BUY Strong Buy
+33.5% avg upside
12 analysts
$260.00
36.53% Upside
 -1.7% ·
DE:SRT3
Sartorius
 Aug 20, 2026 BUY Strong Buy
+18.2% avg upside
19 analysts
$300.00
25.96% Upside
 -3.9% ·
DE:MRK
Merck KGaA
 Aug 20, 2026 HOLD Buy
+2.4% avg upside
34 analysts
$150.00
11.50% Upside
 -1.5% ·
GB:0QIU
Novo Nordisk
 Aug 05, 2026 HOLD Hold
+34.8% avg upside
29 analysts
$332.00
11.06% Upside
 · ·
GB:AZN
AstraZeneca
 Aug 04, 2026 BUY Strong Buy
+23.8% avg upside
26 analysts
$17600.00
48.26% Upside
 -0.2% ·
FR:SAN
Sanofi
 Jul 31, 2026 HOLD Strong Buy
+29.1% avg upside
30 analysts
$78.00
4.39% Upside
 +2.4% ·
CH:GALD
Galderma Group AG
 Jul 24, 2026 BUY Strong Buy
+16.3% avg upside
10 analysts
$200.00
22.98% Upside
 -8.6% ·
GB:GSK
GlaxoSmithKline
 Jul 13, 2026 HOLD Hold
+6.1% avg upside
25 analysts
$1940.00
7.93% Upside
 -3.8% ·
CH:ROP
Roche Holding AG
 May 13, 2026 BUY Buy
-4.7% avg upside
23 analysts
$376.00
7.31% Upside
 +10.6% ·
MRK
Merck & Company
 Nov 01, 2024 BUY Strong Buy
-8.5% avg upside
43 analysts
$125.00
15.80% Downside
 -12.5% ·
CH:LONN
Lonza Group Ltd
 Jan 27, 2022 BUY Strong Buy
+16.2% avg upside
21 analysts
$750.00
34.91% Upside
 -15.1% ·
FR:IPN
Ipsen
 Feb 11, 2020 HOLD Hold
-23.0% avg upside
17 analysts
$72.00
54.68% Downside
 +7.8% ·
NVO
Novo Nordisk
 Nov 02, 2018 HOLD Buy
+151.3% avg upside
26 analysts
$310.00
583.27% Upside
 +32.3% ·
NVS
Novartis
 Jul 05, 2017 SELL Buy
-12.1% avg upside
24 analysts
 — +4.0% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matthew Weston — Frequently Asked Questions
How accurate are Matthew Weston's stock ratings?
Based on the calls 13Foresight could measure, about 53% of Matthew's ratings were profitable over a one-year hold, with an average return of +2.2% per rating, or -97.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Matthew ranked on 13Foresight?
Matthew Weston is currently ranked #621 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on DE:BAYN, CH:NOVN, FR:DIM, DE:SRT3, DE:MRK, GB:0QIU, GB:AZN, FR:SAN, CH:GALD, GB:GSK, CH:ROP, MRK and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.